Glycopyrrolate
ANDA 209328, held by Fresenius Kabi USA. Glycopyrrolate.
- First approved: Oct 27, 2017
- Review: Standard
- Supplements approved: 0
- Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2017 | Original application | Approved | None posted |
Products
1 strengths and forms| Product | Active ingredient | Marketing |
|---|---|---|
| Glycopyrrolate0.2MG/ML · injectable;injection | Glycopyrrolate | Rx |
Identifiers
- Application
- ANDA 209328
- Drugs@FDA
- Overview at FDA
- Company
- Fresenius Kabi USA
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters